<?xml version="1.0" encoding="UTF-8"?>
<OAI-PMH xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.openarchives.org/OAI/2.0/ http://www.openarchives.org/OAI/2.0/OAI-PMH.xsd">
  <responseDate>2024-05-03T09:57:25Z</responseDate>
  <request verb="GetRecord" identifier="oai:pubmedcentral.nih.gov:8783811" metadataPrefix="pmc">https:/www.ncbi.nlm.nih.gov/pmc/oai/oai.cgi</request>
  <GetRecord>
    <record>
      <header>
        <identifier>oai:pubmedcentral.nih.gov:8783811</identifier>
        <datestamp>2022-02-04</datestamp>
        <setSpec>jimmthercanc</setSpec>
        <setSpec>pmc-open</setSpec>
      </header>
      <metadata>
        <article xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xsi:schemaLocation="https://jats.nlm.nih.gov/ns/archiving/1.3/ https://jats.nlm.nih.gov/archiving/1.3/xsd/JATS-archivearticle1-3.xsd" dtd-version="1.3" xml:lang="en" article-type="brief-report">
          <processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats">
            <restricted-by>pmc</restricted-by>
          </processing-meta>
          <front>
            <journal-meta>
              <journal-id journal-id-type="nlm-ta">J Immunother Cancer</journal-id>
              <journal-id journal-id-type="iso-abbrev">J Immunother Cancer</journal-id>
              <journal-id journal-id-type="hwp">jitc</journal-id>
              <journal-id journal-id-type="publisher-id">jitc</journal-id>
              <journal-title-group>
                <journal-title>Journal for Immunotherapy of Cancer</journal-title>
              </journal-title-group>
              <issn pub-type="epub">2051-1426</issn>
              <publisher>
                <publisher-name>BMJ Publishing Group</publisher-name>
                <publisher-loc>BMA House, Tavistock Square, London, WC1H 9JR</publisher-loc>
              </publisher>
            </journal-meta>
            <article-meta>
              <article-id pub-id-type="accession">PMC8783811</article-id>
              <article-id pub-id-type="pmcid">PMC8783811</article-id>
              <article-id pub-id-type="pmc-uid">8783811</article-id>
              <article-id pub-id-type="pmid">35058326</article-id>
              <article-id pub-id-type="publisher-id">jitc-2021-003697</article-id>
              <article-id pub-id-type="doi">10.1136/jitc-2021-003697</article-id>
              <article-categories>
                <subj-group subj-group-type="heading">
                  <subject>Clinical/Translational Cancer Immunotherapy</subject>
                </subj-group>
                <subj-group subj-group-type="hwp-journal-coll">
                  <subject>1506</subject>
                  <subject>2435</subject>
                </subj-group>
              </article-categories>
              <title-group>
                <article-title>Targeting CD38 and PD-1 with isatuximab plus cemiplimab in patients with advanced solid malignancies: results from a phase I/II open-label, multicenter study</article-title>
              </title-group>
              <contrib-group>
                <contrib id="author-90921170" contrib-type="author" equal-contrib="yes">
                  <name>
                    <surname>Zucali</surname>
                    <given-names>Paolo Andrea</given-names>
                  </name>
                  <xref rid="aff1" ref-type="aff">1</xref>
                </contrib>
                <contrib id="author-73648398" contrib-type="author" equal-contrib="yes">
                  <contrib-id contrib-id-type="orcid" authenticated="false">http://orcid.org/0000-0002-2573-5789</contrib-id>
                  <name>
                    <surname>Lin</surname>
                    <given-names>Chia-Chi</given-names>
                  </name>
                  <xref rid="aff2" ref-type="aff">2</xref>
                </contrib>
                <contrib id="author-84336325" contrib-type="author">
                  <name>
                    <surname>Carthon</surname>
                    <given-names>Bradley C</given-names>
                  </name>
                  <xref rid="aff3" ref-type="aff">3</xref>
                  <xref rid="aff4" ref-type="aff">4</xref>
                </contrib>
                <contrib id="author-75228265" contrib-type="author">
                  <name>
                    <surname>Bauer</surname>
                    <given-names>Todd M</given-names>
                  </name>
                  <xref rid="aff5" ref-type="aff">5</xref>
                  <xref rid="aff6" ref-type="aff">6</xref>
                </contrib>
                <contrib id="author-90921249" contrib-type="author">
                  <name>
                    <surname>Tucci</surname>
                    <given-names>Marcello</given-names>
                  </name>
                  <xref rid="aff7" ref-type="aff">7</xref>
                </contrib>
                <contrib id="author-74116911" contrib-type="author">
                  <contrib-id contrib-id-type="orcid" authenticated="false">http://orcid.org/0000-0002-8540-5351</contrib-id>
                  <name>
                    <surname>Italiano</surname>
                    <given-names>Antoine</given-names>
                  </name>
                  <xref rid="aff8" ref-type="aff">8</xref>
                </contrib>
                <contrib id="author-90921301" contrib-type="author">
                  <name>
                    <surname>Iacovelli</surname>
                    <given-names>Roberto</given-names>
                  </name>
                  <xref rid="aff9" ref-type="aff">9</xref>
                </contrib>
                <contrib id="author-86069036" contrib-type="author">
                  <name>
                    <surname>Su</surname>
                    <given-names>Wu-Chou</given-names>
                  </name>
                  <xref rid="aff10" ref-type="aff">10</xref>
                </contrib>
                <contrib id="author-75756445" contrib-type="author">
                  <name>
                    <surname>Massard</surname>
                    <given-names>Christophe</given-names>
                  </name>
                  <xref rid="aff11" ref-type="aff">11</xref>
                  <xref rid="aff12" ref-type="aff">12</xref>
                </contrib>
                <contrib id="author-89021568" contrib-type="author">
                  <name>
                    <surname>Saleh</surname>
                    <given-names>Mansoor</given-names>
                  </name>
                  <xref rid="aff13" ref-type="aff">13</xref>
                </contrib>
                <contrib id="author-90921360" contrib-type="author">
                  <name>
                    <surname>Daniele</surname>
                    <given-names>Gennaro</given-names>
                  </name>
                  <xref rid="aff14" ref-type="aff">14</xref>
                </contrib>
                <contrib id="author-90921385" contrib-type="author">
                  <name>
                    <surname>Greystoke</surname>
                    <given-names>Alastair</given-names>
                  </name>
                  <xref rid="aff15" ref-type="aff">15</xref>
                </contrib>
                <contrib id="author-84941306" contrib-type="author">
                  <name>
                    <surname>Gutierrez</surname>
                    <given-names>Martin</given-names>
                  </name>
                  <xref rid="aff16" ref-type="aff">16</xref>
                </contrib>
                <contrib id="author-74334919" contrib-type="author">
                  <name>
                    <surname>Pant</surname>
                    <given-names>Shubham</given-names>
                  </name>
                  <xref rid="aff17" ref-type="aff">17</xref>
                </contrib>
                <contrib id="author-82249276" contrib-type="author">
                  <name>
                    <surname>Shen</surname>
                    <given-names>Ying-Chun</given-names>
                  </name>
                  <xref rid="aff2" ref-type="aff">2</xref>
                </contrib>
                <contrib id="author-90921461" contrib-type="author">
                  <name>
                    <surname>Perrino</surname>
                    <given-names>Matteo</given-names>
                  </name>
                  <xref rid="aff1" ref-type="aff">1</xref>
                </contrib>
                <contrib id="author-90921479" contrib-type="author">
                  <name>
                    <surname>Meng</surname>
                    <given-names>Robin</given-names>
                  </name>
                  <xref rid="aff18" ref-type="aff">18</xref>
                </contrib>
                <contrib id="author-90921489" contrib-type="author">
                  <name>
                    <surname>Abbadessa</surname>
                    <given-names>Giovanni</given-names>
                  </name>
                  <xref rid="aff18" ref-type="aff">18</xref>
                </contrib>
                <contrib id="author-90921505" contrib-type="author">
                  <name>
                    <surname>Lee</surname>
                    <given-names>Helen</given-names>
                  </name>
                  <xref rid="aff18" ref-type="aff">18</xref>
                </contrib>
                <contrib id="author-90921524" contrib-type="author">
                  <name>
                    <surname>Dong</surname>
                    <given-names>Yingwen</given-names>
                  </name>
                  <xref rid="aff19" ref-type="aff">19</xref>
                </contrib>
                <contrib id="author-88086476" contrib-type="author">
                  <name>
                    <surname>Chiron</surname>
                    <given-names>Marielle</given-names>
                  </name>
                  <xref rid="aff20" ref-type="aff">20</xref>
                </contrib>
                <contrib id="author-89756256" contrib-type="author">
                  <name>
                    <surname>Wang</surname>
                    <given-names>Rui</given-names>
                  </name>
                  <xref rid="aff21" ref-type="aff">21</xref>
                </contrib>
                <contrib id="author-93765634" contrib-type="author">
                  <name>
                    <surname>Loumagne</surname>
                    <given-names>Laure</given-names>
                  </name>
                  <xref rid="aff22" ref-type="aff">22</xref>
                </contrib>
                <contrib id="author-90921597" contrib-type="author">
                  <name>
                    <surname>Lépine</surname>
                    <given-names>Lucie</given-names>
                  </name>
                  <xref rid="aff23" ref-type="aff">23</xref>
                </contrib>
                <contrib id="author-90921633" contrib-type="author" corresp="yes">
                  <name>
                    <surname>de Bono</surname>
                    <given-names>Johann</given-names>
                  </name>
                  <xref rid="aff24" ref-type="aff">24</xref>
                  <xref rid="aff25" ref-type="aff">25</xref>
                </contrib>
              </contrib-group>
              <aff id="aff1"><label>1</label><institution content-type="department">Department of Biomedical Sciences</institution>, <institution>IRCCS Istituto Clinico Humanitas</institution>, <addr-line content-type="city">Rozzano</addr-line>, <country>Italy</country></aff>
              <aff id="aff2"><label>2</label><institution content-type="department">Department of Oncology</institution>, <institution>National Taiwan University Hospital</institution>, <addr-line content-type="city">Taipei</addr-line>, <country>Taiwan</country></aff>
              <aff id="aff3"><label>3</label><institution content-type="department">Department of Hematology and Medical Oncology</institution>, <institution>Emory University School of Medicine</institution>, <addr-line content-type="city">Atlanta</addr-line>, <addr-line content-type="state">Georgia</addr-line>, <country>USA</country></aff>
              <aff id="aff4"><label>4</label><institution content-type="department">Department of Hematology and Medical Oncology</institution>, <institution>Emory University Winship Cancer Institute</institution>, <addr-line content-type="city">Atlanta</addr-line>, <addr-line content-type="state">Georgia</addr-line>, <country>USA</country></aff>
              <aff id="aff5"><label>5</label><institution content-type="department">Drug Development</institution>, <institution>Sarah Cannon Research Institute</institution>, <addr-line content-type="city">Nashville</addr-line>, <addr-line content-type="state">Tennessee</addr-line>, <country>USA</country></aff>
              <aff id="aff6"><label>6</label><institution content-type="department">Medical Oncology</institution>, <institution>Tennessee Oncology</institution>, <addr-line content-type="city">Nashville</addr-line>, <addr-line content-type="state">Tennessee</addr-line>, <country>USA</country></aff>
              <aff id="aff7"><label>7</label><institution content-type="department">Medical Oncology</institution>, <institution>Cardinal Massaia Hospital of Asti</institution>, <addr-line content-type="city">Asti</addr-line>, <country>Italy</country></aff>
              <aff id="aff8"><label>8</label><institution content-type="department">Precision Medicine</institution>, <institution>Gustave Roussy</institution>, <addr-line content-type="city">Villejuif</addr-line>, <country>France</country></aff>
              <aff id="aff9"><label>9</label><institution content-type="department">Medical and Surgical Sciences</institution>, <institution>Fondazione Policlinico Universitario Agostino Gemelli IRCCS</institution>, <addr-line content-type="city">Roma</addr-line>, <country>Italy</country></aff>
              <aff id="aff10"><label>10</label><institution content-type="department">Division of Oncology, Department of Internal Medicine</institution>, <institution>National Cheng Kung University College of Medicine</institution>, <addr-line content-type="city">Tainan</addr-line>, <country>Taiwan</country></aff>
              <aff id="aff11"><label>11</label><institution content-type="department">DITEP, University Paris-Saclay, Faculty of Medicine</institution>, <institution>Gustave Roussy Cancer Campus</institution>, <addr-line content-type="city">Villejuif</addr-line>, <country>France</country></aff>
              <aff id="aff12"><label>12</label><institution content-type="department">DITEP</institution>, <institution>Institut Gustave-Roussy</institution>, <addr-line content-type="city">Villejuif</addr-line>, <country>France</country></aff>
              <aff id="aff13"><label>13</label><institution content-type="department">Department of Medicine</institution>, <institution>The University of Alabama at Birmingham</institution>, <addr-line content-type="city">Birmingham</addr-line>, <addr-line content-type="state">Alabama</addr-line>, <country>USA</country></aff>
              <aff id="aff14"><label>14</label><institution content-type="department">Early Phase Trials Unit</institution>, <institution>Istituto Nazionale Tumori IRCCS Fondazione Pascale</institution>, <addr-line content-type="city">Napoli</addr-line>, <country>Italy</country></aff>
              <aff id="aff15"><label>15</label><institution content-type="department">Newcastle University Centre for Cancer</institution>, <institution>Newcastle University</institution>, <addr-line content-type="city">Newcastle upon Tyne</addr-line>, <country>UK</country></aff>
              <aff id="aff16"><label>16</label><institution content-type="department">Gastrointestinal Medical Oncology, Thoracic Medical Oncology</institution>, <institution>Hackensack University Medical Center</institution>, <addr-line content-type="city">Hackensack</addr-line>, <addr-line content-type="state">New Jersey</addr-line>, <country>USA</country></aff>
              <aff id="aff17"><label>17</label><institution content-type="department">Department of Gastrointestinal Medical Oncology</institution>, <institution>University of Texas MD Anderson Cancer Center</institution>, <addr-line content-type="city">Houston</addr-line>, <addr-line content-type="state">Texas</addr-line>, <country>USA</country></aff>
              <aff id="aff18"><label>18</label><institution content-type="department">Oncology Early Development</institution>, <institution>Sanofi Genzyme</institution>, <addr-line content-type="city">Cambridge</addr-line>, <addr-line content-type="state">Massachusetts</addr-line>, <country>USA</country></aff>
              <aff id="aff19"><label>19</label><institution content-type="department">Biostatistics Oncology Late Phase</institution>, <institution>Sanofi</institution>, <addr-line content-type="city">Cambridge</addr-line>, <addr-line content-type="state">Massachusetts</addr-line>, <country>USA</country></aff>
              <aff id="aff20"><label>20</label><institution content-type="department">Research and Development</institution>, <institution>Sanofi-Aventis</institution>, <addr-line content-type="city">Vitry-sur-Seine</addr-line>, <country>France</country></aff>
              <aff id="aff21"><label>21</label><institution content-type="department">Precision Medicine</institution>, <institution>Sanofi Genzyme</institution>, <addr-line content-type="city">Cambridge</addr-line>, <addr-line content-type="state">Massachusetts</addr-line>, <country>USA</country></aff>
              <aff id="aff22"><label>22</label><institution content-type="department">Translational Medicine</institution>, <institution>Sanofi-Aventis</institution>, <addr-line content-type="city">Paris</addr-line>, <country>France</country></aff>
              <aff id="aff23"><label>23</label><institution content-type="department">Pharmacokinetics</institution>, <institution>Excelya on behalf of Sanofi</institution>, <addr-line content-type="city">Alfortville</addr-line>, <country>France</country></aff>
              <aff id="aff24"><label>24</label><institution content-type="department">Experimental Cancer Medicine</institution>, <institution>The Institute of Cancer Research</institution>, <addr-line content-type="city">London</addr-line>, <country>UK</country></aff>
              <aff id="aff25"><label>25</label><institution content-type="department">Experimental Cancer Medicine</institution>, <institution>Royal Marsden Hospital NHS Trust</institution>, <addr-line content-type="city">London</addr-line>, <country>UK</country></aff>
              <author-notes>
                <corresp><label>Correspondence to</label> Professor Johann de Bono; <email>Johann.de-Bono@icr.ac.uk</email></corresp>
              </author-notes>
              <pub-date pub-type="collection">
                <year>2022</year>
              </pub-date>
              <pub-date pub-type="epub">
                <day>20</day>
                <month>1</month>
                <year>2022</year>
              </pub-date>
              <volume>10</volume>
              <issue>1</issue>
              <elocation-id>e003697</elocation-id>
              <history>
                <date date-type="accepted">
                  <day>07</day>
                  <month>12</month>
                  <year>2021</year>
                </date>
              </history>
              <permissions>
                <copyright-statement>© Author(s) (or their employer(s)) 2022. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ.</copyright-statement>
                <copyright-year>2022</copyright-year>
                <ali:free_to_read/>
                <license>
                  <ali:license_ref specific-use="textmining" content-type="ccbynclicense" start_date="2022-01-19">https://creativecommons.org/licenses/by-nc/4.0/</ali:license_ref>
                  <license-p>This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited, appropriate credit is given, any changes made indicated, and the use is non-commercial. See <ext-link ext-link-type="uri" xlink:href="https://creativecommons.org/licenses/by-nc/4.0/">http://creativecommons.org/licenses/by-nc/4.0/</ext-link>.</license-p>
                </license>
              </permissions>
              <self-uri xlink:title="pdf" xlink:href="jitc-2021-003697.pdf"/>
              <abstract>
                <sec>
                  <title>Background</title>
                  <p>Preclinical data suggest that concurrent treatment of anti-CD38 and antiprogrammed death 1 (PD-1)/programmed death ligand 1 (PD-L1) antibodies substantially reduce primary tumor growth by reversing T-cell exhaustion and thus enhancing anti-PD-1/PD-L1 efficacy.</p>
                </sec>
                <sec>
                  <title>Methods</title>
                  <p>This phase I/II study enrolled patients with metastatic castration-resistant prostate cancer (mCRPC) or advanced non-small cell lung cancer (NSCLC). The primary objectives of phase I were to investigate the safety and tolerability of isatuximab (anti-CD38 monoclonal antibody)+cemiplimab (anti-PD-1 monoclonal antibody, Isa+Cemi) in patients with mCRPC (naïve to anti-PD-1/PD-L1 therapy) or NSCLC (progressed on anti-PD-1/PD-L1-containing therapy). Phase II used Simon’s two-stage design with response rate as the primary endpoint. An interim analysis was planned after the first 24 (mCRPC) and 20 (NSCLC) patients receiving Isa+Cemi were enrolled in phase II. Safety, immunogenicity, pharmacokinetics, pharmacodynamics, and antitumor activity were assessed, including CD38, PD-L1, and tumor-infiltrating lymphocytes in the tumor microenvironment (TME), and peripheral immune cell phenotyping.</p>
                </sec>
                <sec>
                  <title>Results</title>
                  <p>Isa+Cemi demonstrated a manageable safety profile with no new safety signals. All patients experienced ≥1 treatment-emergent adverse event. Grade≥3 events occurred in 13 (54.2%) patients with mCRPC and 12 (60.0%) patients with NSCLC. Based on PCWG3 criteria, assessment of best overall response with Isa+Cemi in mCRPC revealed no complete responses (CRs), one (4.2%) unconfirmed partial response (PR), and five (20.8%) patients with stable disease (SD). Per RECIST V.1.1, patients with NSCLC receiving Isa+Cemi achieved no CR or PR, and 13 (65%) achieved SD. In post-therapy biopsies obtained from patients with mCRPC or NSCLC, Isa+Cemi treatment resulted in a reduction in median CD38+ tumor-infiltrating immune cells from 40% to 3%, with no consistent modulation of PD-L1 on tumor cells or T regulatory cells in the TME. The combination triggered a significant increase in peripheral activated and cytolytic T cells but, interestingly, decreased natural killer cells.</p>
                </sec>
                <sec>
                  <title>Conclusions</title>
                  <p>The present study suggests that CD38 and PD-1 modulation by Isa+Cemi has a manageable safety profile, reduces CD38+ immune cells in the TME, and activates peripheral T cells; however, such CD38 inhibition was not associated with significant antitumor activity. A lack of efficacy was observed in these small cohorts of patients with mCRPC or NSCLC.</p>
                </sec>
                <sec>
                  <title>Trial registration numbers</title>
                  <p><ext-link xlink:href="NCT03367819" ext-link-type="uri">NCT03367819</ext-link>.</p>
                </sec>
              </abstract>
              <kwd-group>
                <kwd>programmed cell death 1 receptor</kwd>
                <kwd>clinical trials as topic</kwd>
                <kwd>drug therapy</kwd>
                <kwd>combination</kwd>
                <kwd>prostatic neoplasms</kwd>
                <kwd>lung neoplasms</kwd>
              </kwd-group>
              <funding-group specific-use="FundRef">
                <award-group id="funding-1">
                  <funding-source>
                    <institution-wrap>
                      <institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/100004339</institution-id>
                      <institution>Sanofi</institution>
                    </institution-wrap>
                  </funding-source>
                </award-group>
              </funding-group>
              <custom-meta-group>
                <custom-meta>
                  <meta-name>special-feature</meta-name>
                  <meta-value>unlocked</meta-value>
                </custom-meta>
              </custom-meta-group>
            </article-meta>
          </front>
          <body>
            <sec id="s1">
              <title>Background</title>
              <p>CD38 belongs to the ADP-ribosyl cyclase family and is widely expressed on the surfaces of immune cells and non-hematopoietic cells.<xref rid="R1" ref-type="bibr">1</xref> The receptor/ligand activity of CD38 has been demonstrated in several types of immune cells, with function varying during development, activation, and differentiation of lymphocytes.<xref rid="R1" ref-type="bibr">1</xref> CD38 is implicated in non-canonical adenosine synthesis, and its overexpression on tumor cells has been implicated in T-cell exhaustion and resistance to immune checkpoint blockade.<xref rid="R2" ref-type="bibr">2</xref> CD38+ tumor-infiltrating immune cell density has been shown to increase following progression to castration-resistant prostate cancer, with an association observed with worse overall survival.<xref rid="R3" ref-type="bibr">3</xref> Preclinical data in lung cancer suggest that concurrent treatment with anti-CD38 and antiprogrammed death 1 (PD-1)/programmed death ligand 1 (PD-L1) antibodies substantially reduces primary tumor growth by suppressing acquired resistance to immune checkpoint blockade, thus enhancing and prolonging anti-PD-1/PD-L1 efficacy.<xref rid="R2" ref-type="bibr">2</xref></p>
              <p>Based on the phase III ICARIA-MM study, isatuximab (Sarclisa) is approved in a number of countries in combination with pomalidomide and dexamethasone for the treatment of adult patients with relapsed/refractory multiple myeloma who have received at least two prior therapies, including lenalidomide and a proteasome inhibitor. Based on the phase III IKEMA study, isatuximab in combination with carfilzomib and dexamethasone is approved in the USA for the treatment of adult patients with relapsed or refractory multiple myeloma who have received one to three prior lines of therapy, and in the European Union for the treatment of adult patients with multiple myeloma who have received at least one prior therapy.<xref rid="R4" ref-type="bibr">4 5</xref></p>
              <p>Cemiplimab (Libtayo) is an anti-PD-1 antibody approved for the treatment of the following: (1) patients with metastatic cutaneous squamous cell carcinoma or locally advanced cutaneous squamous cell carcinoma who are not candidates for curative surgery or curative radiation; (2) patients with locally advanced or metastatic basal cell carcinoma previously treated with a hedgehog pathway inhibitor or for whom a hedgehog pathway inhibitor is not appropriate; and (3) patients with non-small cell lung cancer (NSCLC) and high tumor PD-L1 expression as determined by a Food and Drug Administration-approved test, with no <italic toggle="yes">EGFR</italic>, <italic toggle="yes">ALK</italic>, or <italic toggle="yes">ROS1</italic> aberrations, and is locally advanced, where patients are not candidates for surgical resection or definitive chemoradiation, or metastatic.<xref rid="R6" ref-type="bibr">6</xref></p>
              <p>This study was designed to evaluate the combination of isatuximab plus cemiplimab (Isa+Cemi) in patients with metastatic castration-resistant prostate cancer (mCRPC) or advanced NSCLC.</p>
            </sec>
            <sec sec-type="methods" id="s2">
              <title>Methods</title>
              <sec id="s2-1">
                <title>Study design and objectives</title>
                <p>This was an open-label, multicenter, phase I/II study designed to evaluate the safety, preliminary efficacy, and pharmacokinetics (PK) of Isa+Cemi in patients with mCRPC or NSCLC. The primary objectives of phase I, the safety run-in, were to characterize the safety and tolerability of Isa+Cemi in patients with mCRPC (naïve to anti-PD-1/PD-L1 therapy) or NSCLC (progressed on anti-PD-1/PD-L1-containing therapy) and to confirm the recommended phase II dose (RP2D). The primary objective of phase II, using Simon’s two-stage design, was to assess the response rate of Isa+Cemi in patients with mCRPC or NSCLC.</p>
              </sec>
              <sec id="s2-2">
                <title>Treatment</title>
                <p>Patients received isatuximab 10 mg/kg intravenously every week for 3 weeks (one cycle, 21 days) followed by once every 3 weeks+cemiplimab 350 mg intravenously every 3 weeks. The end of treatment occurred 30 (±7) days following final administration or on receipt of another anticancer therapy, whichever occurred first.</p>
                <p>CT/MRI and bone scans were completed every 9 weeks starting at the end of cycle 3. When treating beyond RECIST V.1.1-defined tumor progression, subsequent assessments were based on iRECIST criteria.</p>
              </sec>
              <sec id="s2-3">
                <title>Immunohistochemistry (IHC) and multiplex immunofluorescence assays</title>
                <p>Single-plex IHC assays used PD-L1 (Ventana, SPC263, ready-to-use) or CD38 (Leica, SPC32, working concentration 1:400) optimized for detection with the OptiView DAB IHC Detection kit on the Ventana Benchmark Ultra platform.</p>
                <p>Patients with paired screening and on-treatment biopsies were selected for the multiplexed immunofluorescent platform (MultiOmyx) analysis, using a pair of Cy3-labeled or Cy5-labeled antibodies per round of staining. Formalin-fixed paraffin-embedded tissues were stained with a customized panel to quantify infiltrating immune cells in the tumor microenvironment (TME) according to the vendor-recommended protocol (Neogenomics).</p>
              </sec>
              <sec id="s2-4">
                <title>Flow cytometry immunophenotyping</title>
                <p>Lymphocyte phenotyping panels capable of detecting CD45 (clone 2D1), CD3 (clone SK7), CD4 (clone SK3), CD8 (clone SK1), CD16 (clone B73.1), CD56 (clone NCAM16.2), CD19 (clone SJ25C1), NKp46 (clone 9e2), HLA-DR (clone L243), granzyme B (clone GB11), and Ki67 (clone Ki67) were used to characterize key functional immune cells.</p>
                <p>Blood samples were collected in Cyto-Chex BCT tubes. Whole blood samples were incubated with fluorescently labeled antibodies specific to the surface markers listed previously followed by red blood cell lysis. Samples were subsequently fixed, permeabilized, and stained with anti-Ki67 and antigranzyme B fluorochrome-conjugated antibodies. Specimens were acquired on the FACSCanto II flow cytometer and results were analyzed using FlowJo V.7 software (FlowJo LLC).</p>
              </sec>
              <sec id="s2-5">
                <title>Pharmacokinetic analysis</title>
                <p>Blood samples were taken at selected time points for PK evaluation of isatuximab and cemiplimab (days 1, 4, 8, and 15) over the first cycle and then mainly at predose. Isatuximab (plasma) and cemiplimab (serum) concentrations were determined using validated immunoassays with lower limits of quantification of 5 µg/mL (isatuximab) and 0.078 mg/L (cemiplimab). Non-compartmental analyses were conducted for both compounds with Phoenix WinNonlin V.8.1 (Pharsight).</p>
              </sec>
              <sec id="s2-6">
                <title>Statistical analysis</title>
                <p>The efficacy and safety analyses were conducted using the all-treated population. Data from mCRPC and NSCLC cohorts in phase II were analyzed and reported separately using descriptive statistics. Continuous data were summarized using mean, standard deviation, median, minimum, and maximum. Categorical and ordinal data were summarized using number and percentage. A 90% two-sided CI was computed using the Clopper-Pearson method for overall response rate (see <xref rid="SP1" ref-type="supplementary-material">online supplemental information</xref> for further details).</p>
                <supplementary-material id="SP1" position="float" content-type="local-data">
                  <object-id pub-id-type="doi">10.1136/jitc-2021-003697.supp1</object-id>
                  <label>Supplementary data</label>
                  <p>
                    <inline-supplementary-material id="SS1" xlink:href="jitc-2021-003697supp001.pdf" content-type="local-data"/>
                  </p>
                </supplementary-material>
              </sec>
            </sec>
            <sec sec-type="results" id="s3">
              <title>Results</title>
              <sec id="s3-1">
                <title>Patients</title>
                <p>Patients with mCRPC had a median age of 69.5 years, and 15 (62.5%) had an Eastern Cooperative Oncology Group (ECOG) performance score of 1. Patients with NSCLC had a median age of 65.5 years, 14 (70.0%) were men, and 11 (55.0%) had an ECOG performance score of 1 (<xref rid="T1" ref-type="table">table 1</xref>). At diagnosis, 54.2% of patients with mCRPC had stage IV disease; all patients had metastatic adenocarcinoma with documented disease progression at study entry. Among patients with NSCLC, 12 (60.0%) had adenocarcinoma, 4 (20.0%) had squamous cell carcinoma and 3 (15.0%) had unspecified NSCLC. At study entry, 15 (75.0%) patients had metastatic disease; 3 (15.0%) had locally advanced disease; and 2 (10.0%) had primary disease. Patients with NSCLC were excluded if they had known <italic toggle="yes">EGFR</italic> sensitizing mutations, <italic toggle="yes">ALK</italic> rearrangement, <italic toggle="yes">ROS1</italic> rearrangement, or <italic toggle="yes">BRAF</italic> mutation. Patients had to receive one previous anti-PD-1/PD-L1 (nivolumab, pembrolizumab, atezolizumab, durvalumab, avelumab, or cemiplimab)-containing regimen (defined as monotherapy or an anti-PD-1/PD-L1 agent administered in the same cycle as another systemic therapy) as the most recent prior therapy to treat stage IIIB/IV or inoperable recurrent NSCLC. Patients were enrolled who had documented benefit (defined as CR, PR, or stable disease (SD) at ≥1 radiographic imaging scan) but subsequent progression per RECIST V.1.1 during the PD-1/PD-L1-containing regimen within 4 months prior to initiation of study treatment.</p>
                <table-wrap position="float" id="T1">
                  <label>Table 1</label>
                  <caption>
                    <p>Summary of demographics and other baseline characteristics—all-treated population</p>
                  </caption>
                  <table frame="hsides" rules="groups">
                    <thead>
                      <tr>
                        <td align="left" valign="bottom" rowspan="1" colspan="1"/>
                        <td align="left" valign="bottom" rowspan="1" colspan="1">mCRPC<break/>(n=24)</td>
                        <td align="left" valign="bottom" rowspan="1" colspan="1">NSCLC<break/>(n=20)</td>
                      </tr>
                    </thead>
                    <tbody>
                      <tr>
                        <td align="left" valign="top" rowspan="1" colspan="1">Age (years)</td>
                        <td align="left" valign="top" rowspan="1" colspan="1"/>
                        <td align="left" valign="top" rowspan="1" colspan="1"/>
                      </tr>
                      <tr>
                        <td align="left" valign="top" rowspan="1" colspan="1"><named-content content-type="indent"> </named-content>Median (range)</td>
                        <td align="char" char="." valign="top" rowspan="1" colspan="1">69.5 (61–88)</td>
                        <td align="char" char="." valign="top" rowspan="1" colspan="1">65.5 (53–77)</td>
                      </tr>
                      <tr>
                        <td align="left" valign="top" rowspan="1" colspan="1">Gender, n (%)</td>
                        <td align="left" valign="top" rowspan="1" colspan="1"/>
                        <td align="left" valign="top" rowspan="1" colspan="1"/>
                      </tr>
                      <tr>
                        <td align="left" valign="top" rowspan="1" colspan="1"><named-content content-type="indent"> </named-content>Male</td>
                        <td align="char" char="." valign="top" rowspan="1" colspan="1">24 (100)</td>
                        <td align="char" char="." valign="top" rowspan="1" colspan="1">14 (70.0)</td>
                      </tr>
                      <tr>
                        <td align="left" valign="top" rowspan="1" colspan="1"><named-content content-type="indent"> </named-content>Female</td>
                        <td align="char" char="." valign="top" rowspan="1" colspan="1">0</td>
                        <td align="char" char="." valign="top" rowspan="1" colspan="1">6 (30.0)</td>
                      </tr>
                      <tr>
                        <td align="left" valign="top" rowspan="1" colspan="1">Race, n (%)</td>
                        <td align="left" valign="top" rowspan="1" colspan="1"/>
                        <td align="left" valign="top" rowspan="1" colspan="1"/>
                      </tr>
                      <tr>
                        <td align="left" valign="top" rowspan="1" colspan="1"><named-content content-type="indent"> </named-content>White</td>
                        <td align="char" char="." valign="top" rowspan="1" colspan="1">18 (75.0)</td>
                        <td align="char" char="." valign="top" rowspan="1" colspan="1">10 (50.0)</td>
                      </tr>
                      <tr>
                        <td align="left" valign="top" rowspan="1" colspan="1"><named-content content-type="indent"> </named-content>Black or African–American</td>
                        <td align="char" char="." valign="top" rowspan="1" colspan="1">0</td>
                        <td align="char" char="." valign="top" rowspan="1" colspan="1">1 (5.0)</td>
                      </tr>
                      <tr>
                        <td align="left" valign="top" rowspan="1" colspan="1">Asian</td>
                        <td align="char" char="." valign="top" rowspan="1" colspan="1">6 (25.0)</td>
                        <td align="char" char="." valign="top" rowspan="1" colspan="1">5 (25.0)</td>
                      </tr>
                      <tr>
                        <td align="left" valign="top" rowspan="1" colspan="1">Not reported or unknown</td>
                        <td align="char" char="." valign="top" rowspan="1" colspan="1">0</td>
                        <td align="char" char="." valign="top" rowspan="1" colspan="1">4 (20.0)</td>
                      </tr>
                      <tr>
                        <td align="left" valign="top" rowspan="1" colspan="1">ECOG performance status, n (%)</td>
                        <td align="left" valign="top" rowspan="1" colspan="1"/>
                        <td align="left" valign="top" rowspan="1" colspan="1"/>
                      </tr>
                      <tr>
                        <td align="char" char="." valign="top" rowspan="1" colspan="1"> 0</td>
                        <td align="char" char="." valign="top" rowspan="1" colspan="1">9 (37.5)</td>
                        <td align="char" char="." valign="top" rowspan="1" colspan="1">9 (45.0)</td>
                      </tr>
                      <tr>
                        <td align="char" char="." valign="top" rowspan="1" colspan="1"> 1</td>
                        <td align="char" char="." valign="top" rowspan="1" colspan="1">15 (62.5)</td>
                        <td align="char" char="." valign="top" rowspan="1" colspan="1">11 (55.0)</td>
                      </tr>
                    </tbody>
                  </table>
                  <table-wrap-foot>
                    <fn id="T1_FN1">
                      <p>ECOG, Eastern Cooperative Oncology Group; mCRPC, metastatic castration-resistant prostate cancer; NSCLC, non-small cell lung cancer.</p>
                    </fn>
                  </table-wrap-foot>
                </table-wrap>
                <p>All patients with mCRPC had received ≥1 prior androgen receptor-targeted agent. Most patients (n=17) had received ≤2 previous taxane-based chemotherapy regimens; 16 received curative or palliative radiation therapy; and 18 underwent prior surgery. All patients with NSCLC had received one previous anti-PD-1/PD-L1-containing regimen as the most recent therapy; 14 had received prior chemotherapy; 12 had received one regimen and two received ≥2 regimens; 10 patients had received prior radiation therapy; and 8 underwent prior surgery.</p>
              </sec>
              <sec id="s3-2">
                <title>Safety</title>
                <p>For patients with mCRPC, the median number of cycles started was 4.5 (range 1–13) and the median duration of exposure to study treatment was 13.5 (range 3–39) weeks. Overall, 21/24 (87.5%) treated patients started ≥2 treatment cycles; 6 patients (25.0%) had ≥1 cycle delayed. The average median cumulative dose of isatuximab was 72.32 mg/kg and the median duration of exposure was 13.5 (range 1–39) weeks.</p>
                <p>For patients with NSCLC, the median number of cycles started was 5.0 (range 1–19), and the median duration of exposure to study treatment was 17.0 (range 3–58) weeks. Overall, 17/20 (85.0%) treated patients started ≥2 treatment cycles; 8 patients (40.0%) had ≥1 cycle delayed. The average median cumulative dose of isatuximab was 70.03 mg/kg, and the median duration of exposure was 17.0 (range 1–58) weeks.</p>
                <p>Isa+Cemi demonstrated a manageable safety profile with no new safety signals. No dose-limiting toxicities were observed, and the RP2D was the standard regimen for each drug. All patients experienced ≥1 treatment-emergent adverse event (TEAE). Grade≥3 TEAEs occurred in 13 (54.2%) patients with mCRPC and 12 (60.0%) patients with NSCLC (<xref rid="T2" ref-type="table">table 2</xref>). No grade 5 TEAEs were related to study treatment. The most frequently reported TEAEs of any grade for both cohorts were infusion-related reactions (mCRPC, 50.0%; NSCLC, 45.0%) (<xref rid="SP1" ref-type="supplementary-material">online supplemental table 1</xref>). Grade≥3 TEAEs reported in &gt;1 patient included infusion-related reactions (mCRPC, 8.3%; NSCLC, 10.0%) and pneumonia (NSCLC, 10.0%; not immune-related). All 24 patients with mCRPC discontinued treatment (progressive disease (PD), n=15; adverse events (AEs), n=4; other, n=4; withdrawal by subject due to AE, n=1). Among patients with NSCLC, 18 (90%) discontinued treatment (PD, n=13; AEs, n=3; other, n=2).</p>
                <table-wrap position="float" id="T2">
                  <label>Table 2</label>
                  <caption>
                    <p>Overview of TEAEs—all-treated population</p>
                  </caption>
                  <table frame="hsides" rules="groups">
                    <thead>
                      <tr>
                        <td align="left" valign="bottom" rowspan="1" colspan="1">n (%)</td>
                        <td align="left" valign="bottom" rowspan="1" colspan="1">mCRPC<break/>(n=24)</td>
                        <td align="left" valign="bottom" rowspan="1" colspan="1">NSCLC<break/>(n=20)</td>
                      </tr>
                    </thead>
                    <tbody>
                      <tr>
                        <td align="left" valign="top" rowspan="1" colspan="1">Patients with any TEAE (any grade)</td>
                        <td align="char" char="." valign="top" rowspan="1" colspan="1">24 (100)</td>
                        <td align="char" char="." valign="top" rowspan="1" colspan="1">20 (100)</td>
                      </tr>
                      <tr>
                        <td align="left" valign="top" rowspan="1" colspan="1">Patients with any TEAE of grade ≥3</td>
                        <td align="char" char="." valign="top" rowspan="1" colspan="1">13 (54.2)</td>
                        <td align="char" char="." valign="top" rowspan="1" colspan="1">12 (60.0)</td>
                      </tr>
                      <tr>
                        <td align="left" valign="top" rowspan="1" colspan="1">Patients with any TEAE of grade 5</td>
                        <td align="char" char="." valign="top" rowspan="1" colspan="1">2 (8.3)</td>
                        <td align="char" char="." valign="top" rowspan="1" colspan="1">2 (10.0)</td>
                      </tr>
                      <tr>
                        <td align="left" valign="top" rowspan="1" colspan="1">Patients with any serious TEAE</td>
                        <td align="char" char="." valign="top" rowspan="1" colspan="1">11 (45.8)</td>
                        <td align="char" char="." valign="top" rowspan="1" colspan="1">13 (65.0)</td>
                      </tr>
                      <tr>
                        <td align="left" valign="top" rowspan="1" colspan="1">Patients with any treatment-related TEAE* (any grade)</td>
                        <td align="char" char="." valign="top" rowspan="1" colspan="1">19 (79.2)</td>
                        <td align="char" char="." valign="top" rowspan="1" colspan="1">14 (70.0)</td>
                      </tr>
                      <tr>
                        <td align="left" valign="top" rowspan="1" colspan="1">Patients with any treatment-related TEAE of grade ≥3</td>
                        <td align="char" char="." valign="top" rowspan="1" colspan="1">4 (16.7)</td>
                        <td align="char" char="." valign="top" rowspan="1" colspan="1">4 (20.0)</td>
                      </tr>
                      <tr>
                        <td align="left" valign="top" rowspan="1" colspan="1">Patients with any serious treatment-related TEAE</td>
                        <td align="char" char="." valign="top" rowspan="1" colspan="1">3 (12.5)</td>
                        <td align="char" char="." valign="top" rowspan="1" colspan="1">3 (15.0)</td>
                      </tr>
                      <tr>
                        <td align="left" valign="top" rowspan="1" colspan="1">Patients with any TEAE leading to definitive study drug discontinuation</td>
                        <td align="char" char="." valign="top" rowspan="1" colspan="1">4 (16.7)</td>
                        <td align="char" char="." valign="top" rowspan="1" colspan="1">3 (15.0)</td>
                      </tr>
                      <tr>
                        <td align="left" valign="top" rowspan="1" colspan="1">Patients with any TEAE leading to premature discontinuation of isatuximab</td>
                        <td align="char" char="." valign="top" rowspan="1" colspan="1">0</td>
                        <td align="char" char="." valign="top" rowspan="1" colspan="1">0</td>
                      </tr>
                      <tr>
                        <td align="left" valign="top" rowspan="1" colspan="1">Patients with any TEAE leading to premature discontinuation of cemiplimab</td>
                        <td align="char" char="." valign="top" rowspan="1" colspan="1">0</td>
                        <td align="char" char="." valign="top" rowspan="1" colspan="1">0</td>
                      </tr>
                      <tr>
                        <td align="left" valign="top" rowspan="1" colspan="1">Patients with any AESI†</td>
                        <td align="char" char="." valign="top" rowspan="1" colspan="1">10 (41.7)</td>
                        <td align="char" char="." valign="top" rowspan="1" colspan="1">10 (50.0)</td>
                      </tr>
                      <tr>
                        <td align="left" valign="top" rowspan="1" colspan="1">Patients with any AESI of grade ≥3</td>
                        <td align="char" char="." valign="top" rowspan="1" colspan="1">3 (12.5)</td>
                        <td align="char" char="." valign="top" rowspan="1" colspan="1">3 (15.0)</td>
                      </tr>
                    </tbody>
                  </table>
                  <table-wrap-foot>
                    <fn id="T2_FN1">
                      <p>*Treatment-related TEAEs are TEAEs related to at least one drug of the combination.</p>
                    </fn>
                    <fn id="T2_FN2">
                      <p>†AESIs include grade ≥2 IARs, grade ≥3 immune-related TEAEs, immune-related AEs of any grade in a patient previously treated with a PI3K inhibitor (only applicable for patients who receive cemiplimab), pregnancy, symptomatic overdose with IMP/NIMP.</p>
                    </fn>
                    <fn id="T2_FN3">
                      <p>AE, adverse event; AESI, adverse event of special interest; IAR, infusion-associated reaction; IMP, investigational medicinal product; mCRPC, metastatic castration-resistant prostate cancer; NIMP, non-investigational medicinal product; NSCLC, non-small cell lung cancer; TEAE, treatment-emergent adverse event.</p>
                    </fn>
                  </table-wrap-foot>
                </table-wrap>
                <p>Immunogenicity was assessed in 39 patients; 1 patient exhibited a cemiplimab-induced antidrug antibody, resulting in an incidence and prevalence of 2.6%. There was no isatuximab-induced antidrug antibody response.</p>
              </sec>
              <sec id="s3-3">
                <title>Efficacy</title>
                <p>Based on PCWG3 criteria,<xref rid="R7" ref-type="bibr">7</xref> assessment of best overall response with Isa+Cemi in patients with mCRPC revealed no complete responses (CRs), 1 (4.2%) unconfirmed partial response (PR), and 5 (20.8%) patients with SD (<xref rid="T3" ref-type="table">table 3</xref>). Per RECIST V.1.1,<xref rid="R8" ref-type="bibr">8</xref> patients with NSCLC receiving Isa+Cemi achieved no CR or PR, and 13 (65.0%) achieved SD (<xref rid="T3" ref-type="table">table 3</xref>). Median progression-free survival was 2.30 months (95% CI 1.91 to 4.27) and 4.01 months (95% CI 1.94 to 4.07) for patients with mCRPC and NSCLC, respectively (<xref rid="SP1" ref-type="supplementary-material">online supplemental figure 1</xref>).</p>
                <table-wrap position="float" id="T3">
                  <label>Table 3</label>
                  <caption>
                    <p>Summary of response rates—all-treated population</p>
                  </caption>
                  <table frame="hsides" rules="groups">
                    <thead>
                      <tr>
                        <td align="left" valign="bottom" rowspan="1" colspan="1"/>
                        <td align="left" valign="bottom" rowspan="1" colspan="1">mCRPC<break/>(n=24)</td>
                        <td align="left" valign="bottom" rowspan="1" colspan="1">NSCLC<break/>(n=20)</td>
                      </tr>
                    </thead>
                    <tbody>
                      <tr>
                        <td align="left" valign="top" rowspan="1" colspan="3">Best overall response, n (%)</td>
                      </tr>
                      <tr>
                        <td align="left" valign="top" rowspan="1" colspan="1"> CR*</td>
                        <td align="char" char="." valign="top" rowspan="1" colspan="1">0</td>
                        <td align="char" char="." valign="top" rowspan="1" colspan="1">0</td>
                      </tr>
                      <tr>
                        <td align="left" valign="top" rowspan="1" colspan="1"> PR*</td>
                        <td align="char" char="." valign="top" rowspan="1" colspan="1">1 (4.2)</td>
                        <td align="char" char="." valign="top" rowspan="1" colspan="1">0</td>
                      </tr>
                      <tr>
                        <td align="left" valign="top" rowspan="1" colspan="1"> Stable disease</td>
                        <td align="char" char="." valign="top" rowspan="1" colspan="1">5 (20.8)</td>
                        <td align="char" char="." valign="top" rowspan="1" colspan="1">13 (65.0)</td>
                      </tr>
                      <tr>
                        <td align="left" valign="top" rowspan="1" colspan="1"> Non-CR/non-PD†</td>
                        <td align="char" char="." valign="top" rowspan="1" colspan="1">9 (37.5)</td>
                        <td align="char" char="." valign="top" rowspan="1" colspan="1">0</td>
                      </tr>
                      <tr>
                        <td align="left" valign="top" rowspan="1" colspan="1"> PD</td>
                        <td align="char" char="." valign="top" rowspan="1" colspan="1">5 (20.8)</td>
                        <td align="char" char="." valign="top" rowspan="1" colspan="1">5 (25.0)</td>
                      </tr>
                      <tr>
                        <td align="left" valign="top" rowspan="1" colspan="1"> Not evaluable‡</td>
                        <td align="char" char="." valign="top" rowspan="1" colspan="1">4 (16.7)</td>
                        <td align="char" char="." valign="top" rowspan="1" colspan="1">2 (10.0)</td>
                      </tr>
                      <tr>
                        <td align="left" valign="top" rowspan="1" colspan="1"> Unconfirmed CR</td>
                        <td align="char" char="." valign="top" rowspan="1" colspan="1">0</td>
                        <td align="char" char="." valign="top" rowspan="1" colspan="1">0</td>
                      </tr>
                      <tr>
                        <td align="left" valign="top" rowspan="1" colspan="1"> Unconfirmed PR</td>
                        <td align="char" char="." valign="top" rowspan="1" colspan="1">1 (4.2)</td>
                        <td align="char" char="." valign="top" rowspan="1" colspan="1">0</td>
                      </tr>
                      <tr>
                        <td align="left" valign="top" rowspan="1" colspan="1">PSA response, n (%)</td>
                        <td align="left" valign="top" rowspan="1" colspan="1"/>
                        <td align="left" valign="top" rowspan="1" colspan="1"/>
                      </tr>
                      <tr>
                        <td align="left" valign="top" rowspan="1" colspan="1"> Responders*</td>
                        <td align="char" char="." valign="top" rowspan="1" colspan="1">1 (4.2)</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">–</td>
                      </tr>
                      <tr>
                        <td align="left" valign="top" rowspan="1" colspan="1"> Unconfirmed response</td>
                        <td align="char" char="." valign="top" rowspan="1" colspan="1">1 (4.2)</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">–</td>
                      </tr>
                      <tr>
                        <td align="left" valign="top" rowspan="1" colspan="3">Overall response, n (%)</td>
                      </tr>
                      <tr>
                        <td align="left" valign="top" rowspan="1" colspan="1"> Responders (CR, PR, or PSA responders)*</td>
                        <td align="char" char="." valign="top" rowspan="1" colspan="1">1 (4.2)</td>
                        <td align="char" char="." valign="top" rowspan="1" colspan="1">0</td>
                      </tr>
                      <tr>
                        <td align="char" char="." valign="top" rowspan="1" colspan="1"> 90% CI§</td>
                        <td align="char" char="." valign="top" rowspan="1" colspan="1">0.2 to 18.3</td>
                        <td align="char" char="." valign="top" rowspan="1" colspan="1">0.0 to 13.9</td>
                      </tr>
                    </tbody>
                  </table>
                  <table-wrap-foot>
                    <fn id="T3_FN1">
                      <p>*Confirmation of response is required.</p>
                    </fn>
                    <fn id="T3_FN2">
                      <p>†Including patients with no target and non-target lesions identified at baseline and no new lesions reported in postbaseline tumor assessments, or patients with only non-target lesions identified at baseline with non-CR/non-PD reported for non-target lesion and no new lesions reported in postbaseline tumor assessments.</p>
                    </fn>
                    <fn id="T3_FN3">
                      <p>‡Including patients with no postbaseline evaluation prior to the initiation of a new anticancer therapy or the data cut-off date.</p>
                    </fn>
                    <fn id="T3_FN4">
                      <p>§Estimated using Clopper-Pearson method.</p>
                    </fn>
                    <fn id="T3_FN5">
                      <p>CR, complete response; mCRPC, metastatic castration-resistant prostate cancer; NSCLC, non-small cell lung cancer; PD, progressive disease; PR, partial response; PSA, prostate-specific antigen.;</p>
                    </fn>
                  </table-wrap-foot>
                </table-wrap>
              </sec>
              <sec id="s3-4">
                <title>Biomarkers</title>
                <p>Baseline levels of CD38+ immune cells, CD38+ tumor cells, PD-L1 tumor-positive score, and tumor-infiltrating immune cells are shown in <xref rid="SP1" ref-type="supplementary-material">online supplemental figure 2</xref>. Isa+Cemi resulted in ~40% median reduction in the proportion of CD38+ tumor-infiltrating immune cells in the TME in post-therapy biopsies from patients with NSCLC or mCRPC (<xref rid="F1" ref-type="fig">figure 1A</xref>; median 40% (range 0.5%–70%) and 3% (range 0%–50%) at baseline and cycle 2 day 1, respectively; n=13). No consistent modulation of PD-L1 expression on tumor cells (<xref rid="F1" ref-type="fig">figure 1B</xref>) or Tregs in the TME (<xref rid="F1" ref-type="fig">figure 1C</xref>) was observed in post-therapy biopsies. The combination triggered a significant increase in peripheral activated and cytolytic T cells, as well as a robust reduction of natural killer (NK) cells (<xref rid="SP1" ref-type="supplementary-material">online supplemental figure 3</xref>).</p>
                <fig position="float" id="F1">
                  <label>Figure 1</label>
                  <caption>
                    <p>mCRPC, metastatic castration-resistant prostate cancer; NSCLC, non-small cell lung cancer; PD-L1, programmed death ligand 1; TPS, tumor-positive score.</p>
                  </caption>
                  <graphic xlink:href="jitc-2021-003697f01" position="float"/>
                </fig>
              </sec>
              <sec id="s3-5">
                <title>Pharmacokinetic analysis</title>
                <p>Results from 33 patients (n=17, NSCLC; n=16, mCRPC) showed consistent isatuximab PK parameters after the first administration across tumor types (<xref rid="SP1" ref-type="supplementary-material">online supplemental table 2</xref>). The mean isatuximab maximum observed concentration (C<sub>max</sub>) and area under the concentration versus time curve over the first 1 week dosing interval (AUC<sub>0–1 week</sub>) was 285 µg/mL and 26 600 µg·h/mL, respectively, with low variability (coefficient of variance (CV) for C<sub>max</sub> and AUC<sub>0–1 week</sub>: 21% and 24%, respectively). At the end of the weekly repeated isatuximab administration, the concentration observed just before the next treatment administration (C<sub>trough</sub>) of cycle 2 showed a twofold higher exposure compared with the first administration and remained within the same magnitude during administration every 3 weeks (Q3W).</p>
                <p>Similar findings were observed for cemiplimab (<xref rid="SP1" ref-type="supplementary-material">online supplemental table 3</xref>), with comparable PK parameters in patients with NSCLC or mCRPC. The mean cemiplimab C<sub>max</sub> and AUC<sub>0–3 weeks</sub> was 106 mg/L and 934 mg·day/L with low variability (CV for C<sub>max</sub> and AUC<sub>0–3 weeks</sub>: 24% and 27%, respectively). After Q3W repeated cemiplimab administration, C<sub>trough</sub> of cycle 5 showed a threefold higher exposure compared with the first administration.</p>
              </sec>
            </sec>
            <sec sec-type="discussion" id="s4">
              <title>Discussion</title>
              <p>Despite advances in treatment, mCRPC remains incurable. Studies have demonstrated promising results in select small subgroups of this patient population with immune checkpoint inhibitors, including anti-PD-1 therapy, contributing to responses with a median duration of greater than 15 months, suggesting benefit for some patients.<xref rid="R9" ref-type="bibr">9–11</xref> PD-1 inhibitors have also demonstrated encouraging results for patients with NSCLC and are licensed for use both alone and in combination with chemotherapy.<xref rid="R12" ref-type="bibr">12</xref> An approach for increasing response to treatment is to identify combinations that synergize with immune checkpoint inhibitor therapy, potentially leading to enhanced therapeutic effects and durability.<xref rid="R13" ref-type="bibr">13</xref></p>
              <p>The rationale for combining anti-CD38 and anti-PD-1 therapies is supported by studies in multiple myeloma, where data have shown that multiple myeloma cells increase expression of PD-1 by NK cells.<xref rid="R14" ref-type="bibr">14</xref> As a result, the PD-1/PD-L1 axis leads to suppressed antibody-dependent cellular toxicity mediated by isatuximab. Moreover, isatuximab reduces the frequency and function of immune-suppressive Tregs.<xref rid="R15" ref-type="bibr">15</xref> Thus, combining anti-PD-1/PD-L1 antibodies with CD38 blockade might lead to a favorable anti-TME and improved therapeutic benefit.<xref rid="R16" ref-type="bibr">16</xref> Additionally, a recent report demonstrates a mechanism of immune resistance to anti-PD-1/PD-L1 therapy caused by tumor CD38 expression in solid tumor animal models, providing a rationale for the combination of isatuximab and cemiplimab in the clinical setting for the prevention of immune checkpoint blockade resistance and the potential positive impact on antitumor activity.<xref rid="R2" ref-type="bibr">2</xref></p>
              <p>This phase I/II study was designed to evaluate the safety, preliminary efficacy, and PK of the combination of isatuximab and cemiplimab in patients with advanced mCRPC or NSCLC. No new safety signals were observed following treatment with Isa+Cemi than what has been published for each drug alone, with both drugs tolerated in combination and no dose-limiting toxicities at the recommended schedules. In the current study, tolerability of Isa+Cemi was similar to that of daratumumab plus atezolizumab based on safety results from a recent study.<xref rid="R17" ref-type="bibr">17</xref> Notably, immune-related TEAEs were reported in one patient each with mCRPC and NSCLC, which is in keeping with previous reports of immune-related TEAEs with similar treatment combinations.<xref rid="R18" ref-type="bibr">18</xref></p>
              <p>Interestingly, in the current study, combination therapy with Isa+Cemi led to a near-40% reduction of CD38+ tumor-infiltrating immune cells in the TME, indicating on-target effects of isatuximab. In addition, following treatment with Isa+Cemi, no consistent modulation of PD-L1 on tumor cells or Tregs in the TME was observed in patient biopsies. However, the low levels of CD38-positive cells and PD-L1-positive cells at baseline may have contributed to difficulties analyzing modulatory responses following treatment. Notably, the combination significantly increased peripheral activated and cytolytic T cells, suggesting that peripheral immune activation was induced by this combination therapy. We also observed peripheral NK cell reduction, which is consistent with previous findings suggesting that isatuximab-mediated NK-cell depletion occurs via exhaustion and CD38/SLAMF7-mediated phagocytosis.<xref rid="R19" ref-type="bibr">19</xref></p>
              <p>Preclinical data demonstrate the synergistic activity of combined anti-CD38 and anti-PD-1 antibodies in murine multiple myeloma cells,<xref rid="R20" ref-type="bibr">20</xref> supporting the investigation of this combination in clinical trials. However, in these small cohorts of patients with mCRPC and NSCLC in the current study, no significant antitumor activity was observed.</p>
              <p>Wu <italic toggle="yes">et al</italic> recently reported results from TCGA database analysis suggesting CD38 expression is positively correlated with survival and infiltrating T cells in patients with NSCLC.<xref rid="R21" ref-type="bibr">21</xref> In addition, using tumor tissue from 45 patients after surgical resection without any prior radiotherapy or chemotherapy, they further confirmed an increased level of CD38+ CD8 T cells in tumor compared with normal tissue, suggesting its potential involvement in the antitumor immune response.</p>
              <p>However, in the present study, we did not observe a significant association of CD38 expression with clinical response. The correlation analysis between CD38 and infiltrated lymphocytes is also not significant. This could be due to (1) difference in prior treatment history: the patients with NSCLC enrolled in present study have progressed from previous anti-PD-1/PD-L1-containing therapy, which could change the baseline CD38 or CD8 expression profile; or (2) limited available biopsies obtained (n=15).</p>
              <p>Isatuximab PK parameters in the current study were comparable with those observed in an ongoing study of isatuximab given alone or in combination with cemiplimab in relapsed/refractory multiple myeloma where the same assay method is used (data on file), suggesting no effect of cemiplimab on isatuximab PK. In addition, PK analyses suggest no effect of isatuximab on cemiplimab PK.<xref rid="R22" ref-type="bibr">22</xref></p>
              <p>The limitation of the current study was the small number of patients enrolled with each tumor type. The strengths of the current study include the demonstration of a manageable safety profile with Isa+Cemi treatment and the biomarker analyses conducted. Additional studies are warranted to further investigate underlying biomarkers that may inform treatment selection and predict benefit from combination therapy with anti-CD38 and anti-PD-1/PD-L1 agents.</p>
              <p>Overall, these results suggest that CD38 and PD-1 modulation by Isa+Cemi has a manageable safety profile, reduces CD38+ immune cells in the TME, and activates peripheral T cells; however, such CD38 inhibition was not associated with significant antitumor activity. A lack of efficacy was observed in these small cohorts of patients with mCRPC and NSCLC.</p>
            </sec>
          </body>
          <back>
            <ack>
              <p>The authors thank the participating patients and their families, and the study centers and investigators for their contributions to the study. Medical writing support was provided by Erin Burns-Tidmore, PhD, of Elevate Medical Affairs, contracted by Sanofi Genzyme for publication support services.</p>
            </ack>
            <fn-group>
              <fn fn-type="other">
                <p><bold>Twitter:</bold> @DrIacovelli</p>
              </fn>
              <fn fn-type="other">
                <p>PAZ and C-CL contributed equally.</p>
              </fn>
              <fn fn-type="other">
                <p><bold>Contributors:</bold> PAZ, C-CL, BCC, TMB, MT, AI, RI, W-CS, CM, MS, GD, AG, MG, SP, Y-CS, MP, and JdB were investigators of the study and contributed to data acquisition. GA, RM, RW, HL, YD, MC, LLo, and LLe designed the study and contributed to data analysis and interpretation. All authors revised this work for important intellectual content and assume responsibility for the integrity of the data and the decision to submit for publication; had full access to the study data; and edited and reviewed manuscript drafts and approved the final draft for submission.</p>
              </fn>
              <fn fn-type="other">
                <p><bold>Funding:</bold> This study was sponsored by Sanofi.</p>
              </fn>
              <fn fn-type="COI-statement">
                <p><bold>Competing interests:</bold> PAZ: Pfizer, Novartis, Sanofi, BMS, MSD, Roche, Amgen, AstraZeneca, Astellas, Janssen, Ipsen, and Bayer. C-CL: Abbvie, BeiGene, Blueprint Medicines, Boehringer Ingelheim, Bristol Myers Squibb, Daiichi Sankyo, Eli Lilly, Novartis, PharmaEngine, and Roche. BCC, MT, W-CS, GD, MS, AG, SP, Y-CS, MP: nothing to disclose. TMB: AstraZeneca, Lilly, Bristol Myers Squibb, Foundation Medicine, Pfizer, Loxo, Bayer, Guardant Health, Exelixis, Blueprint Medicines, and Sanofi. AI: Epizyme, Lilly, Merck Sharp &amp; Dohme, Novartis, Pharmamar, Roche, AstraZeneca, Bayer, Bristol Myers Squibb, Chugai, Pfizer. RI: Ipsen, Pfizer, Janssen, Sanofi, Merck, Astellas, and MSD. CM: Amgen, Astellas, AstraZeneca, Bayer, BeiGene, BMS, Celgene, Debiopharm, Genentech, Ipsen, Janssen, Lilly, MedImmune, MSD, Novartis, Pfizer, Roche, Sanofi, and Orion. MG: Bristol Myers Squibb, Merck, Eli Lilly, Esanex, Foundation Medicine, AstraZeneca, and Guardant 360. RM, GA, HL, YD, MC, RW, and LLo are employed by Sanofi and may hold stock and/or stock options in the company. LLe is employed by Excelya on behalf of Sanofi and may hold stock and/or stock options in the company. JdB: AstraZeneca, GlaxoSmithKline, Pfizer, Taiho, Daiichi Sankyo, Bayer, Orion Pharma, Roche/Genentech, Merck Serono, Sierra Oncology, MSD, Terumo, Menarini/Silicon Biosystems, Astellas, BioexcelTherapeutics, Cellcentric, Merck Sharp &amp; Dohme, Qiagen, Sanofi Aventis, and Vertex Pharmaceuticals.</p>
              </fn>
              <fn fn-type="other">
                <p><bold>Provenance and peer review:</bold> Not commissioned; externally peer reviewed.</p>
              </fn>
              <fn fn-type="other">
                <p><bold>Supplemental material:</bold> This content has been supplied by the author(s). It has not been vetted by BMJ Publishing Group Limited (BMJ) and may not have been peer-reviewed. Any opinions or recommendations discussed are solely those of the author(s) and are not endorsed by BMJ. BMJ disclaims all liability and responsibility arising from any reliance placed on the content. Where the content includes any translated material, BMJ does not warrant the accuracy and reliability of the translations (including but not limited to local regulations, clinical guidelines, terminology, drug names and drug dosages), and is not responsible for any error and/or omissions arising from translation and adaptation or otherwise.</p>
              </fn>
            </fn-group>
            <sec sec-type="data-availability">
              <title>Data availability statement</title>
              <p>Data are available upon reasonable request. Qualified researchers can request access to patient-level data and related study documents including the clinical study report, study protocol with any amendments, blank case report forms, statistical analysis plan, and dataset specifications. Patient-level data will be anonymized, and study documents will be redacted to protect the privacy of trial subjectss. Further details on Sanofi’s data-sharing criteria, eligible studies, and process for requesting access are at <ext-link xlink:href="https://www.clinicalstudydatarequest.com/" ext-link-type="uri">https://www.clinicalstudydatarequest.com</ext-link>.</p>
            </sec>
            <sec sec-type="ethics-statement">
              <title>Ethics statements</title>
              <sec>
                <title>Patient consent for publication</title>
                <p content-type="ethics-consent-to-publish">Not applicable.</p>
              </sec>
              <sec>
                <title>Ethics approval</title>
                <p content-type="ethics-approval">This study involves human participants and was approved by EC (reference: 18/LO/0229IRAS project ID: 239401). The subjects gave informed consent to participate in the study before taking part. The study was conducted in accordance with consensus ethics principles derived from international ethics guidelines, including the Declaration of Helsinki and the ICH guidelines for Good Clinical Practice, and all applicable laws, rules, and regulations. Informed consent was obtained prior to conducting any study-related procedures.</p>
              </sec>
            </sec>
            <ref-list>
              <title>References</title>
              <ref id="R1">
                <label>1</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Quarona</surname><given-names>V</given-names></string-name>, <string-name><surname>Zaccarello</surname><given-names>G</given-names></string-name>, <string-name><surname>Chillemi</surname><given-names>A</given-names></string-name>, <etal>et al</etal></person-group>. <article-title>CD38 and CD157: a long journey from activation markers to multifunctional molecules</article-title>. <source>Cytometry B Clin Cytom</source><year>2013</year>;<volume>84</volume>:<fpage>207</fpage>–<lpage>17</lpage>. <pub-id pub-id-type="doi">10.1002/cyto.b.21092</pub-id><?supplied-pmid http://www.ncbi.nlm.nih.gov/pubmed/23576305?><pub-id pub-id-type="pmid">23576305</pub-id></mixed-citation>
              </ref>
              <ref id="R2">
                <label>2</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Chen</surname><given-names>L</given-names></string-name>, <string-name><surname>Diao</surname><given-names>L</given-names></string-name>, <string-name><surname>Yang</surname><given-names>Y</given-names></string-name>, <etal>et al</etal></person-group>. <article-title>Cd38-Mediated immunosuppression as a mechanism of tumor cell escape from PD-1/PD-L1 blockade</article-title>. <source>Cancer Discov</source><year>2018</year>;<volume>8</volume>:<fpage>1156</fpage>–<lpage>75</lpage>. <pub-id pub-id-type="doi">10.1158/2159-8290.CD-17-1033</pub-id><?supplied-pmid http://www.ncbi.nlm.nih.gov/pubmed/30012853?><pub-id pub-id-type="pmid">30012853</pub-id></mixed-citation>
              </ref>
              <ref id="R3">
                <label>3</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Guo</surname><given-names>C</given-names></string-name>, <string-name><surname>Crespo</surname><given-names>M</given-names></string-name>, <string-name><surname>Gurel</surname><given-names>B</given-names></string-name>, <etal>et al</etal></person-group>. <article-title>Cd38 in advanced prostate cancers</article-title>. <source>Eur Urol</source><year>2021</year>;<volume>79</volume>:<fpage>736</fpage>–<lpage>46</lpage>. <pub-id pub-id-type="doi">10.1016/j.eururo.2021.01.017</pub-id><?supplied-pmid http://www.ncbi.nlm.nih.gov/pubmed/33678520?><pub-id pub-id-type="pmid">33678520</pub-id></mixed-citation>
              </ref>
              <ref id="R4">
                <label>4</label>
                <mixed-citation publication-type="book"><person-group person-group-type="author"><string-name><surname>Aventis</surname><given-names>S</given-names></string-name></person-group>. <source>Sarclisa (isatuximab-irfc). prescribing information</source>. <publisher-loc>Bridgewater, NJ</publisher-loc>: <publisher-name>sanofi-aventis U.S LLC</publisher-name>, <year>2021</year>.</mixed-citation>
              </ref>
              <ref id="R5">
                <label>5</label>
                <mixed-citation publication-type="webpage"><person-group person-group-type="author"><collab>European Medicines Agency</collab></person-group>. <article-title>European public assessment report: Sarclisa (isatuximab)</article-title>, <year>2021</year>. Available: <uri xlink:href="https://www.ema.europa.eu/en/medicines/human/summaries-opinion/sarclisa-0">https://www.ema.europa.eu/en/medicines/human/summaries-opinion/sarclisa-0</uri> [Accessed <comment>21 Jun 2021</comment>].</mixed-citation>
              </ref>
              <ref id="R6">
                <label>6</label>
                <mixed-citation publication-type="webpage"><person-group person-group-type="author"><collab>Regeneron</collab></person-group>. <article-title>Libtayo (cemiplimab). [Prescribing information]</article-title>, <year>2020</year>. Available: <uri xlink:href="https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/761097s005lbl.pdf">https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/761097s005lbl.pdf</uri> [Accessed <comment>5 Apr 2020</comment>].</mixed-citation>
              </ref>
              <ref id="R7">
                <label>7</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Scher</surname><given-names>HI</given-names></string-name>, <string-name><surname>Morris</surname><given-names>MJ</given-names></string-name>, <string-name><surname>Stadler</surname><given-names>WM</given-names></string-name>, <etal>et al</etal></person-group>. <article-title>Trial design and objectives for castration-resistant prostate cancer: updated recommendations from the prostate cancer clinical trials Working group 3</article-title>. <source>J Clin Oncol</source><year>2016</year>;<volume>34</volume>:<fpage>1402</fpage>–<lpage>18</lpage>. <pub-id pub-id-type="doi">10.1200/JCO.2015.64.2702</pub-id><?supplied-pmid http://www.ncbi.nlm.nih.gov/pubmed/26903579?><pub-id pub-id-type="pmid">26903579</pub-id></mixed-citation>
              </ref>
              <ref id="R8">
                <label>8</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Eisenhauer</surname><given-names>EA</given-names></string-name>, <string-name><surname>Therasse</surname><given-names>P</given-names></string-name>, <string-name><surname>Bogaerts</surname><given-names>J</given-names></string-name>, <etal>et al</etal></person-group>. <article-title>New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1)</article-title>. <source>Eur J Cancer</source><year>2009</year>;<volume>45</volume>:<fpage>228</fpage>–<lpage>47</lpage>. <pub-id pub-id-type="doi">10.1016/j.ejca.2008.10.026</pub-id><?supplied-pmid http://www.ncbi.nlm.nih.gov/pubmed/19097774?><pub-id pub-id-type="pmid">19097774</pub-id></mixed-citation>
              </ref>
              <ref id="R9">
                <label>9</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Graff</surname><given-names>JN</given-names></string-name>, <string-name><surname>Alumkal</surname><given-names>JJ</given-names></string-name>, <string-name><surname>Drake</surname><given-names>CG</given-names></string-name>, <etal>et al</etal></person-group>. <article-title>Early evidence of anti-PD-1 activity in enzalutamide-resistant prostate cancer</article-title>. <source>Oncotarget</source><year>2016</year>;<volume>7</volume>:<fpage>52810</fpage>–<lpage>7</lpage>. <pub-id pub-id-type="doi">10.18632/oncotarget.10547</pub-id><?supplied-pmid http://www.ncbi.nlm.nih.gov/pubmed/27429197?><pub-id pub-id-type="pmid">27429197</pub-id></mixed-citation>
              </ref>
              <ref id="R10">
                <label>10</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Tucker</surname><given-names>MD</given-names></string-name>, <string-name><surname>Zhu</surname><given-names>J</given-names></string-name>, <string-name><surname>Marin</surname><given-names>D</given-names></string-name>, <etal>et al</etal></person-group>. <article-title>Pembrolizumab in men with heavily treated metastatic castrate-resistant prostate cancer</article-title>. <source>Cancer Med</source><year>2019</year>;<volume>8</volume>:<fpage>4644</fpage>–<lpage>55</lpage>. <pub-id pub-id-type="doi">10.1002/cam4.2375</pub-id><?supplied-pmid http://www.ncbi.nlm.nih.gov/pubmed/31270961?><pub-id pub-id-type="pmid">31270961</pub-id></mixed-citation>
              </ref>
              <ref id="R11">
                <label>11</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Antonarakis</surname><given-names>ES</given-names></string-name>, <string-name><surname>Piulats</surname><given-names>JM</given-names></string-name>, <string-name><surname>Gross-Goupil</surname><given-names>M</given-names></string-name>, <etal>et al</etal></person-group>. <article-title>Pembrolizumab for treatment-refractory metastatic castration-resistant prostate cancer: Multicohort, open-label phase II KEYNOTE-199 study</article-title>. <source>J Clin Oncol</source><year>2020</year>;<volume>38</volume>:<fpage>395</fpage>–<lpage>405</lpage>. <pub-id pub-id-type="doi">10.1200/JCO.19.01638</pub-id><?supplied-pmid http://www.ncbi.nlm.nih.gov/pubmed/31774688?><pub-id pub-id-type="pmid">31774688</pub-id></mixed-citation>
              </ref>
              <ref id="R12">
                <label>12</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Qu</surname><given-names>J</given-names></string-name>, <string-name><surname>Mei</surname><given-names>Q</given-names></string-name>, <string-name><surname>Liu</surname><given-names>L</given-names></string-name>, <etal>et al</etal></person-group>. <article-title>The progress and challenge of anti-PD-1/PD-L1 immunotherapy in treating non-small cell lung cancer</article-title>. <source>Ther Adv Med Oncol</source><year>2021</year>;<volume>13</volume>:<elocation-id>1758835921992968</elocation-id>. <pub-id pub-id-type="doi">10.1177/1758835921992968</pub-id><?supplied-pmid http://www.ncbi.nlm.nih.gov/pubmed/33643442?><pub-id pub-id-type="pmid">33643442</pub-id></mixed-citation>
              </ref>
              <ref id="R13">
                <label>13</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Han</surname><given-names>HJ</given-names></string-name>, <string-name><surname>Li</surname><given-names>YR</given-names></string-name>, <string-name><surname>Roach</surname><given-names>M</given-names></string-name>, <etal>et al</etal></person-group>. <article-title>Dramatic response to combination pembrolizumab and radiation in metastatic castration resistant prostate cancer</article-title>. <source>Ther Adv Med Oncol</source><year>2020</year>;<volume>12</volume>:<elocation-id>1758835920936084</elocation-id>. <pub-id pub-id-type="doi">10.1177/1758835920936084</pub-id><?supplied-pmid http://www.ncbi.nlm.nih.gov/pubmed/32922519?><pub-id pub-id-type="pmid">32922519</pub-id></mixed-citation>
              </ref>
              <ref id="R14">
                <label>14</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Zhu</surname><given-names>C</given-names></string-name>, <string-name><surname>Song</surname><given-names>Z</given-names></string-name>, <string-name><surname>Wang</surname><given-names>A</given-names></string-name>, <etal>et al</etal></person-group>. <article-title>Isatuximab acts through Fc-dependent, independent, and direct pathways to kill multiple myeloma cells</article-title>. <source>Front Immunol</source><year>2020</year>;<volume>11</volume>:<elocation-id>11</elocation-id>. <pub-id pub-id-type="doi">10.3389/fimmu.2020.01771</pub-id><?supplied-pmid http://www.ncbi.nlm.nih.gov/pubmed/32922390?><pub-id pub-id-type="pmid">32082309</pub-id></mixed-citation>
              </ref>
              <ref id="R15">
                <label>15</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Feng</surname><given-names>X</given-names></string-name>, <string-name><surname>Zhang</surname><given-names>L</given-names></string-name>, <string-name><surname>Acharya</surname><given-names>C</given-names></string-name>, <etal>et al</etal></person-group>. <article-title>Targeting CD38 suppresses induction and function of T regulatory cells to mitigate immunosuppression in multiple myeloma</article-title>. <source>Clin Cancer Res</source><year>2017</year>;<volume>23</volume>:<fpage>4290</fpage>–<lpage>300</lpage>. <pub-id pub-id-type="doi">10.1158/1078-0432.CCR-16-3192</pub-id><?supplied-pmid http://www.ncbi.nlm.nih.gov/pubmed/28249894?><pub-id pub-id-type="pmid">28249894</pub-id></mixed-citation>
              </ref>
              <ref id="R16">
                <label>16</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Li</surname><given-names>Y</given-names></string-name>, <string-name><surname>Yang</surname><given-names>R</given-names></string-name>, <string-name><surname>Chen</surname><given-names>L</given-names></string-name>, <etal>et al</etal></person-group>. <article-title>Cd38 as an immunomodulator in cancer</article-title>. <source>Future Oncol</source><year>2020</year>;<volume>16</volume>:<fpage>2853</fpage>–<lpage>61</lpage>. <pub-id pub-id-type="doi">10.2217/fon-2020-0401</pub-id><?supplied-pmid http://www.ncbi.nlm.nih.gov/pubmed/32857612?><pub-id pub-id-type="pmid">32857612</pub-id></mixed-citation>
              </ref>
              <ref id="R17">
                <label>17</label>
                <mixed-citation publication-type="webpage"><person-group person-group-type="author"><collab>ClinicalTrials.gov</collab></person-group>. <article-title>A study of daratumumab in combination with atezolizumab compared with atezolizumab alone in participants with previously treated advanced or metastatic non-small cell lung cancer (DARZALEX)</article-title>, <year>2019</year>. Available: <uri xlink:href="https://clinicaltrials.gov/ct2/show/NCT03023423">https://clinicaltrials.gov/ct2/show/NCT03023423</uri> [Accessed <comment>19 May 2021</comment>].</mixed-citation>
              </ref>
              <ref id="R18">
                <label>18</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Cohen</surname><given-names>YC</given-names></string-name>, <string-name><surname>Oriol</surname><given-names>A</given-names></string-name>, <string-name><surname>Wu</surname><given-names>KL</given-names></string-name>, <etal>et al</etal></person-group>. <article-title>Daratumumab with Cetrelimab, an anti-PD-1 monoclonal antibody, in relapsed/refractory multiple myeloma</article-title>. <source>Clin Lymphoma Myeloma Leuk</source><year>2021</year>;<volume>21</volume>:<fpage>46</fpage>–<lpage>54</lpage>. <pub-id pub-id-type="doi">10.1016/j.clml.2020.08.008</pub-id><?supplied-pmid http://www.ncbi.nlm.nih.gov/pubmed/33485428?><pub-id pub-id-type="pmid">33485428</pub-id></mixed-citation>
              </ref>
              <ref id="R19">
                <label>19</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Moreno</surname><given-names>L</given-names></string-name>, <string-name><surname>Perez</surname><given-names>C</given-names></string-name>, <string-name><surname>Zabaleta</surname><given-names>A</given-names></string-name>, <etal>et al</etal></person-group>. <article-title>The mechanism of action of the Anti-CD38 monoclonal antibody Isatuximab in multiple myeloma</article-title>. <source>Clin Cancer Res</source><year>2019</year>;<volume>25</volume>:<fpage>3176</fpage>–<lpage>87</lpage>. <pub-id pub-id-type="doi">10.1158/1078-0432.CCR-18-1597</pub-id><?supplied-pmid http://www.ncbi.nlm.nih.gov/pubmed/30692097?><pub-id pub-id-type="pmid">30692097</pub-id></mixed-citation>
              </ref>
              <ref id="R20">
                <label>20</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Verkleij</surname><given-names>CPM</given-names></string-name>, <string-name><surname>Jhatakia</surname><given-names>A</given-names></string-name>, <string-name><surname>Broekmans</surname><given-names>MEC</given-names></string-name>, <etal>et al</etal></person-group>. <article-title>Preclinical rationale for targeting the PD-1/PD-L1 axis in combination with a CD38 antibody in multiple myeloma and other CD38-Positive malignancies</article-title>. <source>Cancers</source><year>2020</year>;<volume>12</volume>. <pub-id pub-id-type="doi">10.3390/cancers12123713</pub-id>. [Epub ahead of print: <comment>10 Dec 2020</comment>].<?supplied-pmid http://www.ncbi.nlm.nih.gov/pubmed/33321969?></mixed-citation>
              </ref>
              <ref id="R21">
                <label>21</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Wu</surname><given-names>P</given-names></string-name>, <string-name><surname>Zhao</surname><given-names>L</given-names></string-name>, <string-name><surname>Chen</surname><given-names>Y</given-names></string-name>, <etal>et al</etal></person-group>. <article-title>CD38 identifies pre-activated CD8+ T cells which can be reinvigorated by anti-PD-1 blockade in human lung cancer</article-title>. <source>Cancer Immunol Immunother</source><year>2021</year>;<volume>70</volume>:<fpage>3603</fpage>–<lpage>16</lpage>. <pub-id pub-id-type="doi">10.1007/s00262-021-02949-w</pub-id><?supplied-pmid http://www.ncbi.nlm.nih.gov/pubmed/33934206?><pub-id pub-id-type="pmid">33934206</pub-id></mixed-citation>
              </ref>
              <ref id="R22">
                <label>22</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Paccaly</surname><given-names>AJ</given-names></string-name>, <string-name><surname>Migden</surname><given-names>MR</given-names></string-name>, <string-name><surname>Papadopoulos</surname><given-names>KP</given-names></string-name>, <etal>et al</etal></person-group>. <article-title>Fixed dose of Cemiplimab in patients with advanced malignancies based on population pharmacokinetic analysis</article-title>. <source>Adv Ther</source><year>2021</year>;<volume>38</volume>:<fpage>2365</fpage>–<lpage>78</lpage>. <pub-id pub-id-type="doi">10.1007/s12325-021-01638-5</pub-id><?supplied-pmid http://www.ncbi.nlm.nih.gov/pubmed/33768419?><pub-id pub-id-type="pmid">33768419</pub-id></mixed-citation>
              </ref>
            </ref-list>
          </back>
        </article>
      </metadata>
    </record>
  </GetRecord>
</OAI-PMH>
